Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2017 (2017), Article ID 6218129, 5 pages
https://doi.org/10.1155/2017/6218129
Clinical Study

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

1Saiyu Kawaguchi Clinic, Kawaguchi, Japan
2Saitama Honoka Clinic, Saitama, Japan
3Saiyu Souka Clinic, Souka, Japan

Correspondence should be addressed to Hiroya Takami; pj.oc.oohay@amurad4545amurad

Received 14 February 2017; Revised 13 May 2017; Accepted 20 July 2017; Published 22 August 2017

Academic Editor: Laszlo Rosivall

Copyright © 2017 Hiroya Takami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Tentori, K. McCullough, R. D. Kilpatrick et al., “High rates of death and hospitalization follow bone fracture among hemodialysis patients,” Kidney International, vol. 85, no. 1, pp. 166–173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. M. Alem, D. J. Sherrard, D. L. Gillen et al., “Increased risk of hip fracture among patients with end-stage renal disease,” Kidney International, vol. 58, no. 1, pp. 396–399, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Wakasugi, J. J. Kazama, M. Taniguchi et al., “Increased risk of hip fracture among Japanese hemodialysis patients,” Journal of Bone and Mineral Metabolism, vol. 31, no. 3, pp. 315–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Iimori, Y. Mori, W. Akita et al., “Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 345–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Jamal, J. A. Hayden, and J. Beyene, “Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis,” The American Journal of Kidney Diseases, vol. 49, no. 5, pp. 674–681, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. L. Lacey, E. Timms, H.-L. Tan et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,” Cell, vol. 93, no. 2, pp. 165–176, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Jamal, Ö. Ljunggren, C. Stehman-Breen et al., “Effects of denosumab on fracture and bone mineral density by level of kidney function,” Journal of Bone and Mineral Research, vol. 26, no. 8, pp. 1829–1835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. G. A. Block, H. G. Bone, L. Fang, E. Lee, and D. Padhi, “A single-dose study of denosumab in patients with various degrees of renal impairment,” Journal of Bone and Mineral Research, vol. 27, no. 7, pp. 1471–1479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. W. C. Liu, J. F. Yen, C. L. Lang, M. T. Yan, and K. C. Lu, “Bisphophonates in CKD patients with low bone mineral density,” The Scientific World Journal, vol. 2013, Article ID 837573, 11 pages, 2013. View at Publisher · View at Google Scholar
  11. S. Dusilová Sulková, J. Horáček, R. Šafránek, P. Gorun, O. Viklický, and V. Palička, “Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature,” Acta Medica, vol. 57, no. 1, pp. 30–33, 2014. View at Publisher · View at Google Scholar
  12. R. Hiramatsu, Y. Ubara, N. Sawa et al., “Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial,” American Journal of Kidney Diseases, vol. 66, no. 1, pp. 175–177, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C.-L. Chen, N.-C. Chen, C.-Y. Hsu et al., “An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 7, pp. 2426–2432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Festuccia, M. T. Jafari, A. Moioli et al., “Safety and efficacy of denosumab in osteoporotic hemodialysed patients,” Journal of Nephrology, vol. 30, no. 2, pp. 271–279, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. B. B. Mccormick, J. Davis, and K. D. Burns, “Severe hypocalcemia following denosumab injection in a hemodialysis patient,” The American Journal of Kidney Diseases, vol. 60, no. 4, pp. 626–628, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Agarwal, E. Csongradi, and A. C. Koch, “Severe symptomatic hypocalcemia after denosumab administration in an end-stage renal disease patient on peritoneal dialysis with controlled secondary hyperparathyroidism,” British Journal of Medicine and Medical Research, vol. 3, no. 4, pp. 1398–1406, 2013. View at Publisher · View at Google Scholar
  17. Y. Maruyama, M. Taniguchi, J. J. Kazama et al., “A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan,” Nephrology Dialysis Transplantation, vol. 29, no. 8, pp. 1532–1538, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. T. M. Keaveny and M. L. Bouxsein, “Theoretical implications of the biomechanical fracture threshold,” Journal of Bone and Mineral Research, vol. 23, no. 10, pp. 1541–1547, 2008. View at Publisher · View at Google Scholar · View at Scopus